Zomedica Corp. ZOMDF revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Zomedica Corp. reported revenue across 3 business segments; the largest, Therapeutics, was $26.2M, 81.8% of the filed sum (+5.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Therapeutics$26.2M81.8%+5.4% yoy
- Development Services$3.03M9.5%no prior
- Diagnostics$2.8M8.7%+15.1% yoy
Members sum to the consolidated $32M for this period.
- Consumables Revenue$20.7M64.6%+17.1% yoy
- Capital Revenue$9.25M28.9%-2.5% yoy
- Engineering Revenue$1.98M6.2%no prior
- Product And Service Other$123K0.4%-6.1% yoy
Members sum to the consolidated $32M for this period.
- United States$26.5M82.6%+17.3% yoy
- Outside the United States$5.57M17.4%+17.8% yoy
Members sum to the consolidated $32M for this period.
- Therapeutics$5.82M66.2%-2.0% yoy
- Development Services$2.01M22.9%no prior
- Diagnostics$966K11.0%+72.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.